Health

Kintor Pharma Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma

SUZHOU, China, May 4, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing inthe United States of its multi-regional pha...

2022-05-04 20:36 2261

United Imaging Flips the Script on its Events Program for 2022, Reveals Expanded Sales Force and U.S. Growth

Its new AE University also  trains new salespeople on the company's unique take on medical imaging purchasing. HOUSTON, May 3, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, said that it has enhanced its U.S. domestic events progr...

2022-05-03 23:22 1955

China Natural Resources Receives Nasdaq Notification Regarding Minimum Bid Requirements

HONG KONG, May 2, 2022  /PRNewswire/ -- On April 27, 2022, China Natural Resources, Inc. (NASDAQ: CHNR) (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Capital Market ("Nasdaq") notifying the Company that it is currently not in compliance with the minimu...

2022-05-03 04:05 1889

WATERDROP ANNOUNCES APPOINTMENT OF NEW INDEPENDENT DIRECTOR

BEIJING, May 2, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced the appointment of Mr.Ning Zhu as a new independent director to its boar...

2022-05-02 20:00 3242

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

SAN DIEGO and SHANGHAI and SYDNEY, April 30, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announces that the U.S. Food and Drug Administration (FDA) has cleared drug candidate IMG-007, a monoclonal antibody against OX40, to proceed to Phase I clinical development. Inmagene is de...

2022-05-01 06:00 3724

Concord Medical Files 2021 Annual Report on Form 20-F

BEIJING, April 29, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers, premium cancer hospitals, and specialty can...

2022-04-30 07:15 3912

IONOVA Announces Clinical Trial Collaboration with MSD to Evaluate INV-1120 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

SHENZHEN, China, April 29, 2022 /PRNewswire/ -- Shenzhen IONOVA Life Science Co., Ltd. announces today it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Kenilworth, NJ., USA) to evaluate clinical benefits of INV-1120, IONOVA's EP4 antagonist, in combination...

2022-04-29 20:00 1111

Waterdrop Files Annual Report on Form 20-F for Fiscal Year 2021

BEIJING, April 28, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it filed its annual report on Form 20-F for the fiscal year ende...

2022-04-29 07:44 3419

Zepp Health Corporation Files 2021 Annual Report on Form 20-F

BEIJING, April 28, 2022 /PRNewswire/ -- Zepp Health Corp. ("Zepp Health" or the "Company") (NYSE: ZEPP), a cloud-based healthcare services provider with world-leading smart wearable technology, today announced that it has filed its annual report on Form 20-F for the full year endedDecember 31, 20...

2022-04-29 05:35 3201

I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer

-  Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO -  Renowned oncology expert Dr. John Hayslip to further accelerate global clinical development of I-Mab's innovative pipeline as CMO SHANGHAI and GAITHE...

2022-04-29 04:01 1618

Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting

Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the treatment of relapsed/refractory multiple myeloma SAN DIEGO, Calif. and SUZHOU, China, April 28, 2022 /PRNewswire/ -- Gracell Biotechnologies ...

2022-04-28 22:30 1953

ReviR Therapeutics Announces Dr. David Dornan as Independent Board Director

SOUTH SAN FRANCISCO, Calif., April 28, 2022 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced today the appointment of Dr.David Dornan as an independent director. "We are thrilled to welcome David to our board of direc...

2022-04-28 22:00 1587

Lunit to Present 11 Abstracts at the 2022 ASCO Annual Meeting

* 7 poster presentations and 4 online publications, including research on AI biomarkers, have been accepted by ASCO * Findings demonstrate the practical effectiveness of Lunit's AI solution in the pathological assessment of cancer SEOUL, South Korea, April 28, 2022 /PRNewswire/ -- Lunit today...

2022-04-28 21:33 1586

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting

TAIPEI, April 28, 2022 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838 ) and Aimmax Therapeutics, Inc. ( United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel ...

2022-04-28 20:00 1388

HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update

* HanAll will expand R&D investments to advance its late-stage pipeline assets   SEOUL, South Korea, April 28, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), a global biopharma company committed to deliver innovative and impactful therapeutics to address severe unmet medical needs, tod...

2022-04-28 19:00 1515

WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability

-   WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goals (SDGs), as well as with its stakeholders' interests in sustainable business performance. -   One example of WuXi Biologics' contribution to society is its rapid, robust pandemic response -- enab...

2022-04-28 08:30 1783

ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting

SUZHOU, China, and ROCKVILLE, MD, April 27, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that updated results from seven studies involving...

2022-04-28 08:18 1516

AIG Announces Widespread Growth in Q1 2022

Results Reflect Growing Demand for High-Quality Live Social Platforms NEW YORK, April 27, 2022 /PRNewswire/ -- Asia Innovations Group (AIG) today announced phenomenal growth in the first quarter of 2022. This growth spans across products, but is especially pronounced in AIG's live social platform...

2022-04-27 22:25 1605

China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement

HANGZHOU, China, April 27, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...

2022-04-27 20:30 1491

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

MELBOURNE, Australia, April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the United Kingdom Medicines & Healt...

2022-04-27 19:40 1573
1 ... 149150151152153154155 ... 273